Wyeth Files Prevnar 13 Vaccine With FDA; GSK Is Step Ahead With Synflorix In Europe
Wyeth is seeking a priority review for its 13-valent pneumococcal vaccine in the U.S., while GSK’s 10-valent version is approved in Europe.
Wyeth is seeking a priority review for its 13-valent pneumococcal vaccine in the U.S., while GSK’s 10-valent version is approved in Europe.